Industry news that matters to you.  Learn more

Researchers Report ScreenCell Usage for Colorectal Cancer – CTC Biomarker

In a recent paper, Cancer Biomarkers (Cancer Biomarkers 14 (2014) p.145–150), researchers at Rouen University Hospital, Rome University Hospital-La Sapienza, and University of Medicine and Pharmacy, Cluj-Napoca, Romania report on the use of the ScreenCell Cyto device to capture and characterize Circulating Tumor Cells (CTCs) from patients with colorectal cancer (CRC). This is the first preliminary report on the use of ScreenCell with samples from CRC patients.

Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics

Genomic Health, Inc. (Nasdaq: GHDX) recently announced that PharmacoEconomics published positive results from a health economic analysis suggesting that use of the Oncotype® DX colon cancer test may result in a significant reduction in direct medical costs and improve patient quality of life by helping them avoid side effects of unnecessary treatment.

IntegraGen Announces Publication of Study with Biomarker Associated with Survival in Metastatic Colorectal Cancer Patients Treated with Drug Therapy

IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism, recently announced the publication of a study in Clinical Cancer Research which reports on the ability of the microRNA (miRNA) miR-31-3p to predict progression-free survival in KRAS wild-type (WT) metastatic colorectal cancer (mCRC) patients treated with anti-epidermal growth factor receptor (EGFR) antibodies.

Sysmex Inostics GmbH to Collaborate with Merck KGaA to Develop and Commercialize a Blood-Based RAS Biomarker Test for Patients with Metastatic Colorectal Cancer

Sysmex Inostics, a subsidiary of Sysmex Corporation, recently announced a collaboration agreement with Merck through its biopharmaceutical division Merck Serono, for the development and commercialization of a RAS kit for patients with metastatic colorectal cancer (mCRC).

QIAGEN Receives FDA Approval of therascreen KRAS RGQ PCR Kit Paired with Second Colorectal Cancer Drug

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) recently announced that its therascreen® KRAS RGQ PCR Kit (therascreen KRAS test) has received U.S. Food and Drug Administration (FDA) approval to guide the treatment of metastatic colorectal cancer patients with Amgen’s Vectibix® (panitumumab). This marks the third FDA approval of a companion diagnostic from QIAGEN that has been paired with a novel medicine.